Table 4 |
|||||
|
Baseline characteristics of BOSpos and BOSneg patients (BOSneg matched and unmatched) and healthy controls and patients with idiopathic pulmonary fibrosisa |
|||||
|
Variables |
BOSpos |
BOSneg (matched) |
BOSneg (unmatched) |
Controls |
IPF |
|
|
|||||
|
Total number |
10 |
10 |
33 |
60 |
25 |
|
Gender, n |
|||||
|
Male |
3 |
4 |
18 |
30 |
18 |
|
Female |
7 |
6 |
15 |
30 |
7 |
|
Mean age (± SD), years |
45.2 ± 15.0 |
45.7 ± 13.1 |
48.2 ± 13.9 |
46.7 ± 11.3 |
64.7 ± 11.3 |
|
Diagnosis, n |
NA |
NA |
|||
|
COPD |
3 |
3 |
8 |
||
|
CF |
4 |
5 |
10 |
||
|
IPF |
1 |
0 |
5 |
||
|
Sarcoidosis |
1 |
0 |
2 |
||
|
α1 antitrypsin deficiency |
1 |
1 |
3 |
||
|
Other |
0 |
1 |
5 |
||
|
Type of graft, n |
NA |
NA |
|||
|
Bilateral |
10 |
10 |
27 |
||
|
Unilateral |
0 |
0 |
6 |
||
|
Survival, mean ± SD, months |
33.6 ± 20.0 |
46.4 ± 9.5 |
51.6 ± 21.3 |
NA |
NA |
|
Mean BOS-free survival (± SD), months |
19.3 ± 12.5 |
46.4 ± 9.5* |
51.6 ± 21.3* |
NA |
NA |
|
BOS grade at diagnosis, n |
NA |
NA |
NA |
NA |
|
|
1 |
7 |
||||
|
2 |
3 |
||||
|
3 |
0 |
||||
|
Histology |
NA |
NA |
NA |
NA |
|
|
Biopsy, histological OB |
4 |
||||
|
Biopsy, no histological OB |
2 |
||||
|
No biopsy |
4 |
||||
|
|
|||||
|
aBOSpos, bronchiolitis obliterans syndrome-positive; BOSneg, bronchiolitis obliterans syndrome-negative; * identical to survival; COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; IPF, idiopathic pulmonary fibrosis; OB, obliterative bronchiolitis; NA, not applicable; SD, standard deviation. |
|||||
|
Kastelijn et al. Fibrogenesis & Tissue Repair 2011 4:24 doi:10.1186/1755-1536-4-24 |
|||||
